← GLP-1 receptor agonists × glycemic control

TrialDiabetes care2004

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Sten Madsbad et al.PubMed ↗Publisher ↗

The primary results report of NCT01509755.

What the trial testedas reported · 190 people · 2004

No range given

Reported lower glycemic control, no range given

−0.75percentage points

As reported

difference −0.75 percentage points, no interval

No range given

Reported lower glycemic control, no range given

−1.80mmol/l

As reported

difference −1.80 mmol/l, no interval

Two numbers in the abstract

the abstract, start to end

In the 0.75-mg liraglutide group, HbA(1c) decreased by 0.75 percentage points (P < 0.0001) and fasting glucose decreased by 1.8 mmol/l (P = 0.0003) compared …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.75
Glycemic control
−1.80
GLP-1 receptor agonistsGlycemic control
1 / 3

73 papers cite itlatest 60 shown

2004
…
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01509755phase 2196 enrolled2000this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 15161785